Our R&D strategy for a thriving product pipeline
As a global biopharmaceutical company with a focus on innovation and specialty care, Ipsen is building a strong and sustainable portfolio of medicines to meet patients’ and their healthcare teams’ needs. We prioritize best-in-class and first-in-class treatments in oncology, rare disease, and neuroscience – areas in which we have proven experience, global capabilities, and a strong network of partners.
Key facts
Investing heavily in R&D
€687m invested in R&D in 2024, sustaining a high-value pipeline.
Precision focus in 3 therapeutic areas
Since 2020, Ipsen has brought in more than 30 programs across our three focus areas of Oncology, Rare disease, and Neuroscience at every stage of development.
Investing in a strong future
Ipsen has been around for around 100 years and plan to be around for another 100. We have significant firepower to invest in the development of next-generation medicines through the pipeline.
Our expert teams and facilities
700 R&D colleagues span three global sites in France, the UK and the US, supported by dedicated research and manufacturing facilities worldwide – including state-of-the-art capabilities in Wrexham, UK to develop and produce neurotoxins.
End-to-end expertise
Ipsen execute across all stages and geographies, leveraging our global footprint, end-to-end capabilities, and scalable operations that flex to portfolio needs.
Building a high-value, sustainable pipeline
Filters
Disease Areas
Phase
Oncology
Rare Diseases
Neuroscience
Group By
Phase – l
Phase – ll
Phase – lll
Registration
IPN01195
(RAFi) Solid tumors
IPN01194
(ERKi) Solid tumors
IPN01203
(TCA) Solid tumors
IPN60300
(ADC) Solid tumors
IPN60340/ICT01
(BTN3A T-cell activator) 1L AML
Tazverik + R2
(EZH2 inhibitor) 2L FL
Tovorafenib
(Type II RAF-kinase inhibitor) 1L pLGG
Iqirvo
(PPAR α/δ agonist) PBC
Iqirvo
(PPAR α/δ agonist) PSC
Bylvay
(IBATi) BA
IPN10200
(recombinant molecule) Cervical dystonia (Tx)
IPN10200
(recombinant molecule) GL, FHL, LCL (Ax)
IPN10200
(recombinant molecule) Migraine (Tx)
IPN10200
(recombinant molecule) AUL (Tx)
Dysport
(BoNTA) Chronic & Episodic migraine
Information shown as of February 2026 – Trials are event-driven & timings can change
| R2 | Lenalidomide + Rituximab |
| EZH2 | Enhancer of zeste homolog |
| 2L | Second Line |
| FL | Follicular Lymphoma |
| RAF | Rapidly Accelerated Fibrosarcoma |
| 1L | First line |
| pLGG | Pediatric Low-Grade Glioma |
| BTN3A | Butyrophilin-3A |
| AML | Acute Myeloid Leukemia |
| ERKi | ERK inhibitor of the MAPK pathway |
| RAFi | RAF inhibitor of the MAPK pathway |
| ADC | Antibody–drug conjugate |
| TCA | T-cell activator |
| IBAT | Ileal Bile Acid Transporter |
| BA | Biliary Atresia |
| PPAR | Peroxisome Proliferator-Activated Receptor |
| PBC | Primary Biliary Cholangitis |
| PSC | Primary Sclerosing Cholangitis |
| BoNTA | Botulinum Toxin Serotype A |
| GL | Glabellar Lines |
| FHL | Forehead Lines |
| LHL | Lateral Canthal Lines |
| AUL | Adult Upper Limb Spasticity |
| Ax | Aesthetics |
| 1 | Executed by Day One Biopharmaceuticals |
Our Partnerships
Ipsen are building a high-impact pipeline driven by external innovation. We seek to build purpose-led partnerships that boost our capacity to improve or extend the lives of people living with cancer, rare diseases and neurological conditions.
Learn moreClinical Trials
Ipsen are building a high-impact pipeline driven by external innovation. We seek to build purpose-led partnerships that boost our capacity to improve or extend the lives of people living with cancer, rare diseases and neurological conditions.